Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
Repligen (RGEN) Stock Price & Analysis
897 Followers
RGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$110.45 - $211.13
Previous Close$183.92
Volume337.96K
Average Volume (3M)549.67K
Market Cap
$10.26B
Enterprise Value$10.22B
Total Cash (Recent Filing)$751.32M
Total Debt (Recent Filing)$711.80M
Price to Earnings (P/E)255.2
Beta1.89
Next Earnings
Apr 24, 2024EPS Estimate
$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding55,771,075
10 Day Avg. Volume390,425
30 Day Avg. Volume549,673
Standard Deviation0.12
R-Squared0.21
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)17.66
Price to Sales (P/S)16.06
Price to Cash Flow (P/CF)88.60
P/FCF Ratio79.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.40
Enterprise Value/Gross Profit35.87
Enterprise Value/Ebitda114.57
Forecast
1Y Price Target
$215.88Price Target Upside17.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Repligen News
PremiumCompany Announcements
Repligen Corp Announces Board Appointment and Compensation Plan
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $110.45 and its highest was $211.13 in the past 12 months.
What is Repligen Corp’s market cap?
Currently, no data Available
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Apr 24, 2024 which is in 5 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Feb 21, 2024. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.326 by $0.004.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is $0.3.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 55,771,076 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.33 in its last earnings report, beating expectations of $0.326. Following the earnings report the stock price went down -2.819%.
Which hedge fund is a major shareholder of Repligen Corp?
Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 269M.
---
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$215.88 (17.38% Upside)
$215.88 (17.38% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 33.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.59%
12-Months-Change
Fundamentals
Return on Equity
2.14%
Trailing 12-Months
Asset Growth
11.87%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q4 2024
0:00 / 0:00
---
RGEN Stock 12 Months Forecast
Average Price Target
$215.88
▲(17.38% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+37.99%
reiterated a buy rating 2 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +37.99% per trade.
---